AIDS-Science Track Award for Research Transition (R03)
Description
Grant Amount: up to $200,000 over a two year period and allows flexibility in budgeting.
The National Institute on Drug Abuse (NIDA) seeks to facilitate the entry of investigators to the area of drug abuse research on HIV/AIDS, including both newly independent investigators (independent of a mentor but without R01 funding) and early career investigators who seek to add research on the intersection of drug abuse and HIV/AIDS to their research programs (applicants may have an existing R01 grant but not one combining drug abuse and HIV/AIDS research). HIV/AIDS research is a major focus at NIDA, but it is often difficult for new investigators to obtain independent funding to generate preliminary data or for early career investigators doing drug abuse or HIV/AIDS research to identify a source of funding that would allow them to expand their research to study the intersection of drug abuse and HIV/AIDS research. To promote the entry of new investigators into research on the natural history, epidemiology, etiology and pathogenesis, prevention, and treatment of HIV/AIDS in drug abusers, this AIDS--Science Track Award for Research Transition (A-START) Funding Opportunity Announcement (FOA) (R03) will support: (1) Pilot or feasibility studies, (2) Secondary analysis of existing data, (3) Small, self-contained research projects, (4) Development of research methodology, and (5) Development of new research technology.
It is expected that investigators who are funded under A-START will use their data to develop R01 grant applications on the intersection of drug abuse and HIV/AIDS.
Funding Organization
National Institute on Drug Abuse
Fund Category
HIV/AIDS
Support Types
Research
Locations
International National
Eligible Organizations
City Agencies Colleges/Universities Commercial Organizations Community Based Organizations County Agencies Educational Organizations/Institutions Federal Government Agencies International Agencies IRS 501 (c)(3) Organizations Nonprofit Organizations Religious Organizations Schools State Agencies Tribal Organizations
Award Amount Notes
The number of awards is contingent upon NIH appropriations, and the submission of a sufficient number of meritorious applications.
Application Due Date
9/7/2015
Project Start Date
4/1/2016
Application Contact
Grants.gov Customer Support , Phone: (800) 518-4726
Technical Contact
Will M Aklin Div of Clinical Neuroscience & Behavioral Research NIDA/NIH/DHHS 6001 Executive Boulevard Rm. 3152, MSC 9593 Bethesda, MD 208929551 Phone: (301) 443-3207 Fax: (301) 443-6814
Fund Duration
Up to 2 years.
Subjects
AIDS Behavioral Research Clinical Research Drug Abuse Epidemiological Research HIV/AIDS Prevention Medical Treatments and Therapies
Audiences
Researchers
Application Process
Applicants must download the SF424 (R&R) application package associated with this funding opportunity using the “Apply for Grant Electronically” button in this FOA or following the directions provided at Grants.gov.
It is critical that applicants follow the instructions in the SF424 (R&R) Application Guide (http://grants.nih.gov/grants/funding/424/SF424_RR_Guide_General_Adobe_VerB.pdf), except where instructed in this funding opportunity announcement to do otherwise. Conformance to the requirements in the Application Guide is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review.
Notes
The FOA provides up to $200,000 support over a two year period and allows flexibility in budgeting, (i.e., funds may be divided evenly over two years or may be divided unevenly, with a maximum of up to $100,000 per year). The funding levels and funding flexibility are designed to accommodate the full range of HIV/AIDS studies that NIDA supports, but the amount requested and allocation of funds between the two years must be justified in the application.
Disclaimer: NPIN provides this information as a public service only. The views and information provided about the materials, funding opportunities, and organizations do not necessarily state or reflect those of the U.S. Department of Health and Human Services, CDC, or NPIN.
